An interventional study of Acute TAVI and Stabilization and subacute TAVI in Aortic Stenosis and Cardiogenic Shock, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 36th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 69th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark, Sweden
Ages 18+
Anteris Technologies Ltd. · Sites in Denmark
Ages 18+
Ole De Backer · Sites in Denmark, Belgium, Finland and 3 more countries
Ages 18+
Sahajanand Medical Technologies Limited · Sites in Denmark
Ages 18–99
Novartis Pharmaceuticals · Sites in Denmark, United States, Austria and 12 more countries
Ages 50–80
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 40 interventional studies, 200 across the 33 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 73 have an industry lead sponsor. The 10 most frequent:
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
Rigshospitalet, Denmark has 7 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06638268Rigshospitalet, DenmarkTranscatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock | 2027-07-01 |
| NCT06470022Christian Juhl TerkelsenComparison of Evolut FX Versus Sapien 3 Ultra Resilia. | 2027-07-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in patients with critical severe aortic stenosis.
The main questions it aims to answer are:
Participants will:
Aortic stenosis (AS) is a condition where the heart's aortic valve narrows. With an estimated prevalence of 12% in individuals aged 75 years and above, it is the most common heart valve disease. The progressive narrowing increases the afterload on the heart, impairing its ability to maintain cardiac output. The end-stage of critical AS is cardiogenic shock (CS) with an incidence of 3.5% to 12%. Without treatment, patients develop acute decompensation, organ failure, and ultimately die.
Guidelines suggest balloon aortic valvuloplasty (BAV), hemodynamic optimization in the intensive care unit and surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) when the patient is stable. Even with BAV, the 30-day mortality is 33%-47% and a 1-year mortality is 70%. Further, the BAV procedure is associated with only a minor and likely temporary reduction in afterload due to elastic valvular tissue. Furthermore, the BAV procedure has been abandoned as a routine intervention in these patients due to a series of patients having limited immediate clinical response, a risk of deterioration and no impact on overall mortality risk. Moreover, most patients with critical AS in CS are not candidates for surgical aortic valve replacement because of increased peri-operative risk of morbidity and mortality.
Despite the recommendation on TAVI under stable conditions, an acute TAVI may be efficient in afterload reduction and more efficient than the limited and transient effects of BAV. TAVI has become an attractive alternative to surgery and BAV because of the less invasive nature of this procedure, yet permanent result (compared with BAV). It is already approved for the treatment of AS irrespective of CS status. This raises the question:
"Should acute TAVI be the new preferred treatment strategy in AS patients in Cardiogenic shock?"
In this randomized controlled trial, we will include patients with severe aortic stenosis and cardiogenic shock. Patients will undergo either acute TAVI or standard treatment (stabilization in a cardiac intensive care unit and subsequently TAVI) in a 1:1 ratio. Outcomes are evaluated 90 days after randomization and comprise days alive out of hospital, mortality, cardiac function, renal function, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AND
Cardiogenic Shock defined as:
OR
- Syncope/resuscitation (mechanical ventilation)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acute TAVI within 12 hours.
Procedure: Acute TAVI
TAVI no earlier than 72 hours.
Other: Stabilization and subacute TAVI
TAVI must be performed as soon as possible and within 12 hours of admission to the heart center.
Patients are stabilized according to target parameters. Treatment may include vasopressor, mechanical ventilation, renal replacement therapy, and blood transfusion. TAVI is then performed no earlier than 72 hours of admission to heart center.
Days alive out of hospital
Days alive out of hospital
Time frame: 90 days post-randomization
Mortality
Rate of all-cause mortality
Time frame: 90 days post-randomization
LVEF
Left ventricular ejection fraction assessed with transthoracic echocardiography
Time frame: 90 days post-randomization
Clinical Frailty Scale
The Clinical Frailty Scale (CFS) is a tool used to assess a patient\'s level of frailty. The CFS ranges from 1 to 9, with higher scores indicating greater frailty.
Time frame: 90 days post-randomization
EQ-5D-5L
The EQ-5D-5L is a standardized instrument used to measure health-related quality of life. It is designed for use in clinical settings, research, and health evaluations, and provides a simple, yet comprehensive measure of a patient\'s overall health status. The \"5D\" refers to the five dimensions of health that it assesses, and the \"5L\" refers to the five levels of severity within each dimension.
Time frame: 90 days post-randomization
N-terminal-pro-brain- natriuretic peptide levels
Meassured in a blood sample
Time frame: 90 days post-randomization
eGFR
Estimated glomerular filtration rate in mL/min/1.73m2 meassured in a blood sample.
Time frame: 90 days post-randomization.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 31 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.